Ivy Natal utilizes a proprietary engineering platform to convert skin cells into human egg cells, addressing infertility by providing a novel source of reproductive cells. This technology aims to enhance fertility treatment options and improve success rates for individuals facing reproductive challenges.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Infertility affects a significant portion of the population, and current fertility treatments are limited by the availability and quality of human egg cells. Obtaining sufficient numbers of high-quality egg cells for procedures like in-vitro fertilization (IVF) remains a major challenge.
Solution
Ivy Natal is developing a novel approach to fertility treatment by engineering skin cells into human egg cells using a proprietary cellular engineering platform. This technology aims to provide a scalable and reliable source of reproductive cells, potentially overcoming the limitations of traditional methods. By transforming readily available skin cells, Ivy Natal seeks to increase the success rates and accessibility of fertility treatments for individuals facing reproductive challenges. The platform leverages machine learning, mRNA/CRISPR biotechnologies, and automated high-throughput laboratory systems to accelerate the development of new fertility solutions.
Target Audience
The primary target audience includes individuals and couples experiencing infertility, as well as fertility clinics and research institutions seeking advanced reproductive technologies.
Features
- Proprietary cellular engineering platform for converting skin cells into human egg cells
- Utilizes machine learning approaches to optimize cell conversion process
- Employs cutting-edge mRNA/CRISPR biotechnologies for precise cellular reprogramming
- Automated, high-throughput laboratory systems for scalable production